文献速递关节外科运动医学

BST-CarGel联合微骨折修复髋臼软骨缺损的临床与影像学结果优于单纯微骨折

Better Clinicoradiological Results of BST-CarGel Treatment in Cartilage Repair Compared With Microfracture in Acetabular Chondral Defects at 2 Years.
PubMed 文献 · Am J Sports Med · 2020-06-10

本研究为队列研究,比较了髋关节镜下微骨折联合BST-CarGel与单纯微骨折治疗髋臼软骨缺损的短期临床与影像学结果。结果显示两组临床评分均显著改善且组间无差异,但CarGel组关节间隙丢失和转为全髋关节置换的比例显著低于微骨折组。

要点

  • 两组iHOT-33和HOS-ADL评分均显著改善,但调整协变量后组间无差异。

核心结论

  • 髋关节镜下BST-CarGel联合微骨折治疗髋臼软骨缺损,相比单纯微骨折,可显著减少关节间隙进行性丢失和全髋关节置换转换率。

研究设计与样本

  • 回顾性队列研究,证据等级3级,纳入2014至2018年因髋臼软骨缺损接受髋关节镜手术并至少随访2年的患者。
  • 3例患者失访。

主要发现

  • 微骨折组iHOT-33从43.24改善至60.17,CarGel组从41.13改善至58.39;HOS-ADL微骨折组从62.25改善至76.75,CarGel组从44.69改善至79.16。
  • 调整协变量后,两组临床 outcome 评分无差异。
  • CarGel组失败病例的平均缺损面积大于微骨折组(分别为8.83 cm²和3.72 cm²)。

临床怎么用

  • 对于髋臼软骨缺损,可考虑在微骨折基础上联合BST-CarGel,以降低关节间隙丢失和全髋关节置换风险。
  • 需注意CarGel组患者缺损面积更大,但转换全髋关节置换的比例更低,提示其可能对较大缺损也有保护作用。

局限性

  • 本研究为队列研究,证据等级3级,非随机分组,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BST-CarGel (CarGel) is an injectable chitosan scaffold that is mixed with fresh, autologous blood and injected into the site of microfracture (MF) to physically stabilize clots and enhance cartilage repair. PURPOSE: To evaluate short-term clinicoradiological outcomes of patients treated arthroscopically for acetabular chondral defects with CarGel in conjunction with MF compared with those treated with MF alone. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: All patients who underwent hip arthroscopy and received MF with or without CarGel for acetabular chondral defects between 2014 and 2018 with a minimum 2-year clinicoradiological follow-up were included. Intraoperative details, postoperative complications, and clinical outcome scores, including the international Hip Outcome Tool-33 (iHOT-33), Hip Outcome Score (HOS)-Activities of Daily Living (HOS-ADL), and Hip Outcome Score-Sports Profile, were analyzed. Serial plain radiographs were assessed independently by 2 blinded observers. A survival analysis was performed to identify the number of cases converted to total hip arthroplasty (THA) in both groups, which was correlated with the cartilage defect size at the time of surgery. RESULTS: Eighty patients (54 CarGel and 26 MF) were evaluated, including 56 men (70%) and 48 right hips (60%). Three patients were lost to follow-up. There were no major adverse events in either group. The average defect size was 3.63 and 4.97 cm2 in MF and CarGel, respectively (P = .002). There was a statistically significant improvement in iHOT-33 (from 43.24 to 60.17 in MF and from 41.13 to 58.39 in CarGel) and HOS-ADL (from 62.25 to 76.75 in MF and from 44.69 to 79.16 in CarGel) scores. There was no difference between the 2 groups in the outcome scores after adjusting for covariates. Survival analysis showed 34.6% of MF cases and 5.9% of CarGel cases were converted to THA (P = .001). The mean defect size of the failure group was higher in CarGel than in MF (8.83 and 3.72 cm2, respectively). Mean joint space reduction was 1.41 mm in MF and 0.19 mm in CarGel (P < .001). CONCLUSION: Two-year clinicoradiological results were promising in these lesions that are difficult to treat. Arthroscopic treatment of chondral acetabular defects with CarGel demonstrated a significant decrease in progressive loss of joint space and conversion to THA compared with MF as an isolated procedure.

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. John R, Ma J, Wong I, et al. Better Clinicoradiological Results of BST-CarGel Treatment in Cartilage Repair Compared With Microfracture in Acetabular Chondral Defects at 2 Years. Am J Sports Med. 2020. PMID: 32520591. doi:10.1177/0363546520924841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。